PMID: 8597611Feb 1, 1996Paper

Trisomy 8 preceding diagnosis of acute nonlymphocytic leukemia by 2 years in a patient with multiple myeloma without cytological evidence of myelodysplasia

Annals of Hematology
H J WehD K Hossfeld

Abstract

A case of acute nonlymphocytic leukemia (ANLL) occurring 2 years after the diagnosis of multiple myeloma (MM) that had been treated by only one course of melphalan/prednisone chemotherapy is reported. Cytogenetic and fluorescence in situ hybridization analysis of peripheral blood cells revealed trisomy 8 as the sole cytogenetic defect at the time of diagnosis of ANLL. Two years earlier, when MM was diagnosed without any cytological evidence of co-existent myelodysplasia, chromosomal analysis of bone marrow cells showed the same pathological karyotype 47, XY, +8 in 14 of 20 mitoses studied. Our interpretation of this unusual cytogenetic finding is that at the time of diagnosis of MM, in spite of lacking cytological signs of myelodysplasia, an unrecognizable myelodysplastic syndrome must have been present which then evolved to ANLL.

References

Jan 1, 1979·Acta Haematologica·G A KastanasH A Nathena
Jul 1, 1991·European Journal of Haematology·B JohanssonF Mitelman
Sep 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N J ChaoS J Forman
May 1, 1991·British Journal of Cancer·A NandakumarS M Schwartz
Nov 1, 1988·Clinical Pediatrics·Z E KurtykaJ J Pietrzyk
May 1, 1983·British Journal of Haematology·G J MuftiC Race

❮ Previous
Next ❯

Citations

Jan 28, 2003·Cancer Genetics and Cytogenetics·M Teresa FerroJavier Lopez
Aug 25, 1999·Cancer Genetics and Cytogenetics·A AmielM Lishner
Jul 17, 2010·Cancer Genetics and Cytogenetics·S PrabhuA Smith
Jun 15, 2004·Cancer Genetics and Cytogenetics·A AmielM Lishner
Aug 13, 2004·American Journal of Hematology·P BernardeschiS Guidi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.